Skip to main content

Table 2 Correlation of clinical features, disease characteristics, treatment, and disease status

From: Vulvar cancer: surgical management and survival trends in a low resource setting

Sl no.

Age (years)

Tumor location

Tumor size

Histology

Chemo/radiotherapy/def

Surgery

Stage

Lymph node

Disease status

F/U time (m)

1

42

U/L (R)

0.5 × 0.5

MM(AM)

ACRT

MRV+B/L

IFLND

pT3N1M0(IVA)

3/28

RD

3

2

60

U/L (R)

0.5 × 0.5

SCC(WD)

ACRT

WLE+B/L

IFLND

FIGO IIIB

7/22

RD

4

34

43

B/L

6.5 × 5.0

SCC(MD)

ACRT

WLE+B/L

IFLND

FIGO IIIB

6/24

RD

3

38

U/L (L)

5.0 × 3.5

SCC(MD)

ART

WLE+B/L

IFLND+Recon*

FIGO IB

0/13

NED

23

5

40

B/L

0.5 × 0.5

SCC(MD)

NACRT

WLE+B/L

IFLND

FIGO IIIB

1/7

NED

12

6

75

U/L (R)

2.5 × 2.5

SCC(PD)

ACRT

WLE+B/L

IFLND

FIGO II

0/8

NED

18

7

75

U/L (L)

6.5 × 4.0

SCC(WD)

Def

WLE+B/L

IFLND

FIGO IIIB

9/16

NED

3

8

60

U/L (L)

1.5 × 1.0

SCC(MD)

Def

RV+B/L (IFLND + PLND)+Recon#

FIGO IIIA

2/20

NED

2

9

57

U/L (R)

5.0 × 3.0

SCC(WD)

 

WLE+B/L

IFLND

FIGO 1B

0/21

NED

59

10

66

U/L (L)

4.5 × 4.5

SCC(WD)

NWA

Palliative

RV

FIGO IIIB

1/20

RD

2

11

44

B/L

6.5 × 6.0

SCC(MD)

Def

WLE+B/L

IFLND

FIGO IIIA

0/13

NED

4

12

84

U/L (L)

5.0 × 4.0

SCC(MD)

ACRT

WLE+B/L

IFLND

FIGO IB

2/18

NED

1

13

56

U/L (R)

3.5 × 2.0

SCC(MD)

NWA

WLE+B/L

IFLND

FIGO IIIB

2/31

NED

30

14

64

U/L (R)

3.5 × 3.0

AS (MD)

NWA

RV + B/L (IFLND+PLND)

FIGO IIIB

1/17

NED

18

15

50

U/L (L)

1.5 × 1.0

MM(NM)

AC

RV+ MRH +B/L (IFLND+PLND)

pT3N1M0

(IVA)

0/12

RD

2

16

52

U/L (R)

4.0 × 2.0

SCC (MD) +VIN III

 

WLE+B/L

IFLND

FIGO IA

9/17

NED

12

17

58

U/L (R)

2.0 × 1.5

SCC(MD)

ART

WLE+B/L

IFLND

FIGO IIIC

0/9

NED

8

18

41

U/L (L)

3.0 × 1.5

SCC(WD)

ART

WLE+B/L

IFLND

FIGO IB

0/12

NED

7

19

65

U/L (R)

2.0 × 1.0

SCC(MD)

ACRT

WLE+ I/L

IFLND

FIGO IB

0/13

NED

6

20

44

U/L (R)

3.0 × 2.0

SCC(MD)

ACRT

WLE+B/L

IFLND

FIGO IIIB

4/14

R

5

  1. Abbreviations: U/L unilateral, B/L bilateral, L left, R right, SCC squamous cell carcinoma, MM malignant melanoma, NM nodular melanoma, AM amelanotic melanoma, AS adenosquamous cell carcinoma, WD well-differentiated, MD moderately differentiated, PD poorly differentiated, VIN vulvar intraepithelial neoplasia, ART adjuvant radiotherapy, ACRT adjuvant chemoradiotherapy, Def defaulted case, NWA not willing for adjuvant treatment, Pall Chemo palliative chemotherapy, WLE wide local excision, RV radical vulvectomy, MRV modified radical vulvectomy, MRH modified radical hysterectomy, IFLND inguinofemoral lymph node dissection, PLND pelvic lymph node dissection, NED no evidence of disease, RD recurrent disease, m month, FIGO International Federation of Gynaecology and Obstetrics, Recon reconstruction
  2. *Reconstruction by V-Y gracilis advancement flap
  3. #Reconstruction by local rotation advancement V-Y fasciocutaneous flap